Search Results - "Ortmann, O."

Message from the Editor-in-Chief by Ortmann, O.

Get full text

Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry by Inwald, E. C., Klinkhammer-Schalke, M., Hofstädter, F., Zeman, F., Koller, M., Gerstenhauer, M., Ortmann, O.

“…The proliferation marker Ki-67 is one of the most controversially discussed parameters for treatment decisions in breast cancer patients. The purpose of this…”
Get full text

Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review by Huber, D., Seitz, S., Kast, K., Emons, G., Ortmann, O.

“…Purpose BRCA mutation carriers have an increased risk of developing breast or ovarian cancer. Oral contraception (OC) is known to increase breast cancer and…”
Get full text

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review by Huber, D., Seitz, S., Kast, K., Emons, G., Ortmann, O.

“…Purpose BRCA mutation carriers have an increased risk of developing breast or ovarian cancer. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is…”
Get full text

Message from the Editor in Chief by Ortmann, O.

Get full text

Message from the Editor-in-Chief by Ortmann, O.

Get full text

Message from the Editor-in-Chief by Ortmann, O.

Get full text

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial by Coombes, RC, Prof, Kilburn, LS, MSc, Snowdon, CF, MSc, Paridaens, R, Prof, Coleman, RE, Prof, Jones, SE, MD, Jassem, J, Prof, Van de Velde, CJH, Prof, Delozier, T, MD, Alvarez, I, MD, Del Mastro, L, MD, Ortmann, O, Prof, Diedrich, K, Prof, Coates, AS, Prof, Bajetta, E, Prof, Holmberg, SB, MD, Dodwell, D, MD, Mickiewicz, E, MD, Andersen, J, DMSc, Lønning, PE, Prof, Cocconi, G, Prof, Forbes, J, Prof, Castiglione, M, Prof, Stuart, N, MD, Stewart, A, MD, Fallowfield, LJ, Prof, Bertelli, G, MD, Hall, E, PhD, Bogle, RG, MD, Carpentieri, M, PhD, Colajori, E, MD, Subar, M, MD, Ireland, E, MSc, Bliss, JM, Prof

“…Summary Background Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or sequentially after…”
Get full text

4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival by Inwald, Elisabeth Christine, Koller, M., Klinkhammer-Schalke, M., Zeman, F., Hofstädter, F., Gerstenhauer, M., Brockhoff, G., Ortmann, O.

“…The aim of the present study was to evaluate to what extent the combination of standard histopathological parameters determines the biology of breast cancer…”
Get full text

Message from the Editor-in-Chief by Ortmann, O.

Get full text

Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review by Huber, D., Seitz, S., Kast, K., Emons, G., Ortmann, O.

“…Purpose Mutations in the genes BRCA1 and BRCA2 represent a significant risk factor for ovarian and breast cancer. With increasing number and success rates,…”
Get full text

Message from the Editor-in-Chief by Ortmann, O.

Get full text

Message from the Editor-in-Chief by Ortmann, O.

Get full text

Message from the Editor-in-Chief by Ortmann, O.

Get full text

Correction to: Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review by Huber, D., Seitz, S., Kast, K., Emons, G., Ortmann, O.

Get full text

Message from Editor-in-Chief by Ortmann, O.

Get full text

The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer by Ortmann, O., Schüler-Toprak, S., Kast, K.

“…Purpose To support doctors in counselling women with genetic predisposition for breast or gynecologic cancers on endocrine interventions. Methods Evidence on…”
Get full text

Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review by Mueck, A. O., Ruan, X., Prasauskas, V., Grob, P., Ortmann, O.

“…In recent years, a vast quantity of clinical data has been accumulated on the pathophysiology of symptomatic vulvovaginal atrophy (VVA)/genitourinary syndrome…”
Get full text

Does cavity margin shaving reduce residual tumor and re‐excision rates? A systematic review by Fernandez‐Pacheco, M., Ortmann, O., Ignatov, A., Inwald, E. C.

“…Purpose Cavity shaving (CS) is a surgical technique used in the treatment of breast cancer (BC). It may reduce margin positivity in histologic assessment and…”
Get full text

Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors by Donders, G., Bellen, G., Neven, P., Grob, P., Prasauskas, V., Buchholz, S., Ortmann, O.

“…This study was a detailed microscopic analysis of the changes of vaginal microflora characteristics after application of 0.03 mg estriol-lactobacilli…”
Get full text